Search Result

Results for "

extravasation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Adrenergic Receptor (1) Biochemical Assay Reagents (1) CCR (1) Dopamine Receptor (1) Endogenous Metabolite (1) Formyl Peptide Receptor (FPR) (2) Integrin (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) Neurokinin Receptor (4) Reference Standards (1) TNF Receptor (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (6) Endocrinology (1) Inflammation/Immunology (11) Neurological Disease (14)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14406A

L-733060 hydrochloride	Neurokinin Receptor	Neurological Disease Cancer
L-733060 hydrochloride is a potent tachykinin NK₁ receptor antagonist. L-733060 hydrochloride inhibits neurogenic plasma extravasation at doses that do not cause adverse cardiovascular effects in rodents and also acts as an antitumoral agent .

HY-103131

PNU-142633	5-HT Receptor	Neurological Disease
PNU-142633 is a high affinity, selective and orally active 5-HT_1D receptor agonist with K_is of 6 nM and > 18 000 nM for human 5-HT_1D receptor and human 5-HT_1B receptor, respectively. PNU-142633 has anti-migraine efficacy .

HY-P99336

Enlimomab BI-RR 0001; Anti-Human IL6 Recombinant Antibody	Integrin	Neurological Disease Inflammation/Immunology
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .

HY-P1118

Ac9-25	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .

HY-172442

Hyaluronidase	Biochemical Assay Reagents	Others
Hyaluronidase is an enzyme that can break down hyaluronic acid. Hyaluronidase can increase the absorption of drugs into tissues and reduce tissue damage in cases of drug extravasation .

HY-103132

PNU109291	5-HT Receptor	Neurological Disease
PNU109291 is a potent and selective 5-HT1D agonist. PNU109291 reduces dural plasma extravasation evoked by trigeminal ganglion stimulation .

HY-P10268

Neuropeptide K (human, porcine, rat)	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger .

HY-P1118A

Ac9-25 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .

HY-117952

L 743310	Neurokinin Receptor	Neurological Disease
L 743310 is a non-peptide, selective antagonist of the human neurokinin hNK1 receptor, with high affinity for primate and cloned human hNK1 receptors and lower affinity for rodent NK1 receptors. L 743310 inhibits resiniferatoxin-induced plasma protein extravasation in guinea pig esophagus. L 743310 has a dose-dependent inhibitory effect on cisplatin-induced emesis .

HY-135487

Sibenadet AR-C68397AA free base; AR-C68397XX	Dopamine Receptor Adrenergic Receptor	Others
Sibenadet (AR-C68397AA (free base)) is a dual dopamine D₂/β₂-adrenoceptor agonist with selective β₂-adrenoceptor agonism. Sibenadet inhibits capsaicin-induced plasma protein extravasation in rat trachea. Sibenadet suppresses edema from sensory nerve fiber activation by activating β₂-adrenoceptor. Sibenadet is promising for research of chronic obstructive pulmonary disease (COPD) .

HY-118378

ZD6021	Neurokinin Receptor	Neurological Disease Endocrinology
ZD6021 is an orally active Neurokinin 1 Receptor antagonist, with K_i values of 0.12 nM for NK1 and 0.62 nM for NK2. At a concentration of 100 nM, ZD6021 has a pK_B value of 8.9 for human pulmonary artery NK1 receptors, and a pK_B value of 7.3 for human bronchial NK2 receptors. ZD6021 effectively reduces ASMSP-induced plasma protein extravasation in guinea pigs, with an ED₅₀ of 0.5 mg/kg, and also decreases NK2 mediated bronchoconstriction, with an ED₅₀ of 13 mg/kg .

HY-P991224

CAP-100	CCR	Inflammation/Immunology Cancer
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .

HY-B0197

Naratriptan GR-85548A	5-HT Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan is an orally active and selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0229

Zolmitriptan BW-311C90; 311C90	5-HT Receptor Endogenous Metabolite	Neurological Disease
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

HY-B0197A

Naratriptan hydrochloride 2 Publications Verification GR-85548A hydrochloride	5-HT Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan (GR-85548A) hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0197S

Naratriptan-d3 GR-85548A-d₃-1	5-HT Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0197AR

Naratriptan hydrochloride (Standard) GR-85548A hydrochloride (Standard)	Reference Standards 5-HT Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan (GR-85548A) hydrochloride (Standard) is the analytical standard of Naratriptan hydrochloride (HY-B0197A). This product is intended for research and analytical applications. Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0197AS

Naratriptan-d3 hydrochloride GR-85548A d₃	5-HT Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-172458

Z-3578	Mas-related G-protein-coupled Receptor (MRGPR) TNF Receptor	Neurological Disease
Z-3578 is a small-molecule antagonist targeting MrgX2 (Mas-related G protein-coupled receptor X2) with significant anti-pseudoallergic activity and a K_D value of 729 nM. Z-3578 effectively inhibits mast cell degranulation induced by substance P (SP) and C48/80, suppressing the release of β-hexosaminidase with IC₅₀ values of 4.90 µM and 6.18 µM, respectively. It also markedly reduces the release of histamine and TNF-α, along with intracellular calcium flux. In a murine pseudoallergy model, Z-3578 significantly alleviates paw swelling and dye extravasation and lowers serum histamine levels, indicating potent in vivo anti-allergic effects. Z-3578 holds promise as a lead compound for the treatment of allergic diseases, especially pseudoallergic reactions .

Ac9-25	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .

Neuropeptide K (human, porcine, rat)	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Neuropeptide K, human, porcine, rat exhibits bioactivity in gallbladder contraction, protein extravasation, hypotension and brcnchial smooth muscle spasm. Neuropeptide K, human, porcine, rat is concentrated in brain and acts as tachykinin neuromessenger .

Ac2-12	Peptides	Inflammation/Immunology
Ac2-12, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models .

Ac2-12 TFA	Peptides	Inflammation/Immunology
Ac2-12 TFA, an annexin/lipocortin 1 (LC1)-mimetic peptide, inhibit neutrophil extravasation. Ac2-12 TFA has antimigratory action and inhibits recruitment of neutrophils in experimental inflammation models .

Ac9-25 TFA	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
Ac9-25 TFA, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR .

Cat. No.	Product Name	Target	Research Area

HY-P99336

Enlimomab BI-RR 0001; Anti-Human IL6 Recombinant Antibody	Integrin	Neurological Disease Inflammation/Immunology
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .

HY-P991224

CAP-100	CCR	Inflammation/Immunology Cancer
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0229

Zolmitriptan BW-311C90; 311C90	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Indole Alkaloids	5-HT Receptor Endogenous Metabolite
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with K_is of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .

Cat. No.	Product Name	Chemical Structure

HY-B0197S

Naratriptan-d3
Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

Naratriptan-d3

Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan (HY-B0197). Naratriptan is a selective 5-HT1B/1D receptor agonist. Naratriptan is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

HY-B0197AS

Naratriptan-d3 hydrochloride
Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

Naratriptan-d3 hydrochloride

Naratriptan-d₃ (GR-85548A-d₃) is the deuterium labeled Naratriptan hydrochloride (HY-B0197A). Naratriptan hydrochloride is a selective 5-HT1B/1D receptor agonist. Naratriptan hydrochloride is peripherally active and has good oral bioavailability, inducing cranial artery vasoconstriction by activating 5-HT1B/1D receptors (EC₅₀=0.11 μM for dog basilar artery). Naratriptan hydrochloride also inhibits trigeminal nerve-mediated dural neurogenic plasma extravasation and reduces sterile inflammation. Naratriptan hydrochloride is mainly used in the research of acute migraine, targeting cranial vascular and neuroinflammatory mechanisms .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks